A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Subjects With Acute Myeloid Leukemia (AML)

Trial Profile

A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Subjects With Acute Myeloid Leukemia (AML)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Aug 2017

At a glance

  • Drugs Entospletinib (Primary) ; Azacitidine; Azacitidine; Cytarabine; Daunorubicin; Decitabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 31 Jul 2017 Planned End Date changed from 1 Dec 2019 to 1 Aug 2019.
    • 12 May 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 12 May 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top